

II. AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended) A method for the prevention of the loss of visual acuity associated with AMD, which comprises, ~~juxtasclerally~~ administering a pharmaceutically effective amount of the compound anecortave acetate or its corresponding alcohol, wherein said administering is by a method selected from the group consisting of posterior juxtasccleral injection, juxtasccleral implant, intravitreal injection, or implant.

Claim 2 (original) The method of claim 1, wherein the compound is administered as a juxtasccleral depot.

Claim 3 (original) The method of claim 2, wherein the depot comprises 3 mg – 30 mg of compound.

Claim 4 (original) The method of claim 3, wherein the depot comprises 15 mg of compound.

Claim 5 (currently amended) A method for maintaining visual acuity in a person suffering from AMD, which comprises ~~juxtascclerally~~ administering a pharmaceutically effective amount of the compound anecortave acetate or its corresponding alcohol, wherein said administering is by a method selected from the group consisting of posterior juxtasccleral injection, juxtasccleral implant, intravitreal injection, or implant.

Claim 6 (original) The method of claim 5, wherein the compound is administered as a juxtasccleral depot.

Claim 7 (original) The method of claim 6, wherein the depot comprises 3 mg – 30 mg of compound.

Claim 8 (original) The method of claim 7, wherein the depot comprises 15 mg of compound.

Claim 9 (currently amended) A method for the inhibition of lesion growth associated with AMD, which comprises ~~juxtasclerally~~ administering a pharmaceutically effective amount of the compound anecortave acetate or its corresponding alcohol, wherein said administering is by a method selected from the group consisting of posterior juxtasceral injection, juxtasceral implant, intravitreal injection, or implant.

Claim 10 (original) The method of claim 9, wherein the compound is administered as a juxtasceral depot.

Claim 11 (original) The method of claim 10, wherein the depot comprises 3 mg – 30 mg of compound.

Claim 12 (original) The method of claim 11, wherein the depot comprises 15 mg of compound.

Claim 13 (original) The method of ~~claim~~ any one of claims 1, 5, or 9, wherein the compound is administered in a juxtasceral implant.

Claim 14 (new) A method for inhibiting blood vessel growth associated with AMD, said method comprising administering a pharmaceutically effective amount of the compound anecortave acetate or its accompanying alcohol, wherein the administering is by juxtasceral injection, intravitreal injection, juxtasceral implant, or other implant.

Serial No.: unknown
Filed: 26 June 2003
Page 4

Claim 15 (new) The method of claim 14, wherein the amount of compound administered is from 3 mg to 30 mg.

Claim 16 (new) The method of claim 15, wherein the amount of compound administered is 15 mg.

Claim 17 (new) The method of claim 9, wherein the lesion is a predominantly classic subfoveal lesion.

Claim 18 (new) The method of claim 9, wherein the lesion is a minimally classic lesion.

III. REMARKS

A. Status of the Claims


Claims 1-13 were originally filed with the case on June 26, 2003. No Office Action has issued in the present case. Claims 1, 5, 9 and 13 are amended herein to clarify the subject matter of the invention. Claims 14-18 are added herein. Support for the amendments can be found throughout the specification and in the claims as originally filed. More specifically, support for amendments to claims 1, 5 and 9 and for new claim 14 can be found at page 10, lines 34-36. Support for new claims 14-16 can also be found at page 1, lines 28-31 and in the claims as originally filed. Support for new claims 17 and 18 can be found at page 6, lines 4-6.

B. Conclusion

Applicants respectfully request that the claims be considered as amended herein.

The Examiner is invited to contact the undersigned attorney at (817) 551-4321 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,



Teresa J. Schultz
Reg. No. 40,526
Attorney for Applicants

ALCON RESEARCH, LTD.
6201 S. Freeway, Q-148
Fort Worth, TX 76134-2099
(817) 551-4321

Date: 16 Oct. 2003